Bloomios Buys CBD Gummy Manufacturer for $23.5 Million

Bloomios expects the added operations to more than double its production capacity.

California-based hemp product manufacturer Bloomios Inc. (OTCQB: BLMS) last week acquired gummy maker Infusionz for $23.5 million in a bid to rapidly expand its gummy manufacturing footprint.

Infusionz owner, the Florida-based Upexi (Nasdaq: UPXI), provided “significant” financing to Infusionz for an undisclosed portion of the deal.

“This acquisition is highly accretive, and we believe that it will position Bloomios to uplist to Nasdaq,” said Barrett Evans, president and chief strategy officer of Bloomios. “Further, it will allow the company to acquire additional complementary manufacturing operations and brands.”

The acquisition includes Infusionz’s CBD portfolio along with its associated order flow, product formulations, manufacturing operations, equipment, and sales team.

The $23.5 million price tag included $5.5 million in cash, as well as $18 million worth of noncash consideration that consisted of a $4.5 million senior secured convertible debenture by Bloomios to Upexi plus a $5 million secured subordinated promissory note and shares of a newly created Series D Convertible Preferred Stock with a value of $8.5 million.

The added operations are expected to more than double Bloomios’ current production capacity while shaving down redundant costs, the company said. Bloomios said that the acquisition will contribute in excess of $22 million in annualized gross revenue.

“This acquisition enables us to better address unmet demand and significantly improve our operational capabilities,” stated Bloomios CEO Michael Hill. “In addition to the new brands and expanded manufacturing capacity, it brings with it a substantial amount of new order flow, positive cash flow, valuable customer relationships, and a highly-capable sales team to drive further growth.”

Bloomios said that it believes the Infusionz brand will launch the company’s expansion into the direct-to-consumer market and other new distribution channels.

The acquisition was funded in part through a senior secured convertible debenture offering with an aggregate principal amount of approximately $13,893,059 (including a 15% original issue discount) led by institutional investors.

The total new investment received in connection with the senior secured convertible debenture offering was $6.25 million with the balance of the principal amount consisting of issuances to Upexi and the refinancing of previous loans.

Revere Securities and Spartan Capital helped facilitate the deal.

Adam Jackson

Adam Jackson covers the cannabis industry for The Green Market Report. He previously covered the Missouri statehouse for The Columbia Missourian and has written for The Missouri Independent. He most recently covered retail, restaurants, and other consumer companies for Bloomberg Business News. You can find him on Twitter @adam_sjackson and email him at adam.jackson@crain.com.


Agrify

Leave a Reply

Your email address will not be published. Required fields are marked *

Choose Your News

Subscribe to the Green Market Report newsletter that gives you original content delivered straight to your inbox.

 Subscribe

By continuing I agree to your Privacy Policy and consent to receive relevant newsletters and other email communications on events, editorial features, and special partner offers from Green Market Report. I can unsubscribe or change my email preferences at any time.


About Us

The Green Market Report focuses on the financial news of the rapidly growing cannabis industry. Our target approach filters out the daily noise and does a deep dive into the financial, business and economic side of the cannabis industry. Our team is cultivating the industry’s critical news into one source and providing open source insights and data analysis


READ MORE



Recent Tweets

@GreenMarketRpt – 28 mins

Illinois Governor Opens Door to Cannabis Delivery

@GreenMarketRpt – 49 mins

NLRB: Curaleaf Violated Labor Law by Refusing to Bargain with Union

@GreenMarketRpt – 2 hours

Medical Insurance Providers Assess Benefits of Psychedelics Treatments

Back to Top

Choose Your News

Subscribe to the Green Market Report newsletter that gives you original content delivered straight to your inbox.

 Subscribe

By continuing I agree to your Privacy Policy and consent to receive relevant newsletters and other email communications on events, editorial features, and special partner offers from Green Market Report. I can unsubscribe or change my email preferences at any time.